At MSKCC, we largely use NavDx as part of our post-operative de-escalation trial in which NavDx is checked pre and post surgery to help select patients for de-escalation. If NavDx becomes undetectable after surgery: In patients with pathologic risk factors that warrant adjuvant RT, patients under...

We are in an exciting time where ctHPVDNA could help direct care, although the best application of such technologies is a little bit unknown.For clinical situations, we use NavDx to help sort out HPV status in patients with ambiguous biopsies. (The lymph node FNAs where there is not enough sample fo...

The multi-disciplinary HN team at MUSC obtains its pre-treatment, mid-treatment (2 weeks postop or week 4 of a course of definitive radiotherapy), at 3 months post-treatment PET and then with every follow-up visit for patients with p16 positive oropharynx squamous cell carcinoma. If positive 2 weeks...

The theoretical benefits are everywhere: escalate/de-escalate adjuvant treatment regimens, potentially stop definitive treatments early if ctDNA cleared, optimize post-treatment surveillance (i.e. help resolve ambiguous imaging findings or potentially even replace routine surveillance imaging entire...

We have been using NavDx in our clinic for p16 and/or HPV-positive patients. The majority of patients have been HN but we have a couple anal and cervix cancers. We obtain pre-treatment, 3 months at PET/CT follow-up, and then every 6 months. We have found it extremely useful to help tiebreak for equ...